RNTXHIGH SIGNALFINANCIAL10-K

RNTX faces severe liquidity constraints with cash declining 75% to $3.2M while pausing multiple development programs and prioritizing only one Phase 2 trial.

The company has shifted from expecting funding needs beyond August 2025 to requiring capital beyond Q2 2026, indicating they secured some financing but remain in precarious financial condition. Management has made the strategic decision to pause LTI-01 and other preclinical programs indefinitely, concentrating resources solely on their LTI-03 Phase 2 trial that began patient screening in May 2025.

Comparing 2026-03-26 vs 2025-04-07View on EDGAR →
FINANCIAL ANALYSIS

RNTX's financial position deteriorated significantly with cash reserves falling 75% to just $3.2M and total assets declining 61% to $24.2M. However, the company managed to reduce operating losses meaningfully, with R&D expenses down 23% and net losses improving from $62.9M to $49.9M. The combination of severely constrained liquidity and improved operational efficiency suggests management is aggressively cutting costs while racing to advance their lead program before capital runs out.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-75%
$12.9M$3.2M

Cash declined 75% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-68.9%
$54.4M$16.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-68.3%
$13.7M$4.3M

Current assets declined 68.3% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-61.2%
$62.2M$24.2M

Total assets contracted 61.2% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-22.6%
$14.2M$11.0M

R&D spending cut 22.6% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+22.2%
-$65.1M-$50.6M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+20.7%
-$62.9M-$49.9M

Net income grew 20.7% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+13.1%
-$22.3M-$19.4M

Operating cash flow grew 13.1% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-04-07
ADDED
As of March 24, 2026 t he Registrant has 28,039,032 shares of Common Stock, $0.001 par value per share, outstanding.
These risks are discussed more fully in the Risk Factors section of this Annual Report.
We will require substantial additional capital to finance our operations beyond the second quarter of 2026 and to complete the development and commercialization of our product candidates.
Due to our current liquidity constraints, we have paused development of LTI 01 and other preclinical programs for an undetermined period and are prioritizing LTI 03.
If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay our clinical and research and development program, future commercialization efforts or other operations.
Risks Related to the Discovery, Development and Commercialization of Product Candidates Our business is highly dependent on the success of our product candidate, LTI-03, which is now screening and recruiting patients in a Phase 2 clinical trial that initiated in May 2025.
We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of LTI-03.
We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI 01 for an undetermined period of time and are prioritizing LTI 03.
In the fourth quarter of 2025, we decided to pause development activities related to LTI-01 and preclinical programs targeting cystic fibrosis and a peptide program focused on the Cav1 protein for an indefinite period.
Three approved drugs, Nerandomilast (Jascayd ), nintedanib (OFEV ) and pirfenidone, have been shown to reduce the rate of lung function decline, but unfortunately provide only modest clinical benefit in IPF patients.
REMOVED
Suite 250 #390 Austin , TX 78758 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code : ( 737 ) 802-1989 Aileron Therapeutics, Inc.
As of March 27, 2025 t he Registrant has 21,992,387 shares of Common Stock, $0.001 par value per share, outstanding.
These risks are discussed more fully in the Risk Factors section of this Annual Report on Form 10-K for the year ended December 31, 2024.
These risks include the following: Risks Related to Our Financial Condition We believe that our existing cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into August 2025, as a result we will need to obtain sufficient additional funding prior to initiating our planned Phase 2 clinical trial of LTI-03.
We will require substantial additional capital to finance our operations beyond August 2025 and to complete the development and commercialization of LTI-03 and LTI-01.
If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our clinical and research and development programs, future commercialization efforts or other operations.
Our cash and cash equivalents are not sufficient to fund operations for at least the next twelve months from the date of issuance of the consolidated financial statements included elsewhere in this Annual Report, which raises substantial doubt about our ability to continue as a going concern.
Risks Related to the Discovery, Development and Commercialization of Product Candidates Our business is highly dependent on the success of our product candidates, LTI-03 and LTI-01 and any other product candidates that we advance into clinical development.
We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of LTI-03, LTI-01 or any other product candidates.
We have entered into a collaboration agreement with Taiho Pharmaceutical Co., Ltd., or Taiho, for the development of LTI-01 in Japan and may in the future seek to enter into collaborations with third parties for the development and commercialization of other product candidates.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →